Roivant Sciences (ROIV) CEO Eric Venker Sells 200,000 Shares

Insider Buying and Selling at Roivant Sciences Ltd.

Eric Venker, President and Immunovant CEO at Roivant Sciences Ltd. (NasdaqGS: ROIV), sold 200,000 shares on June 24, 2026. This transaction follows a busy stretch of executive equity movements at the clinical-stage biopharmaceutical firm, occurring just months before the company's next financial update.

Stock Price and Market Position

Roivant Sciences shares change hands at $34.07, positioning the biotech firm well above its 52-week low of $14.50 while staying below its peak of $42.50. Investors continue to monitor the equity as it moves closer to the scheduled November 9, 2026 earnings release, which will offer fresh details on clinical pipelines and cash deployment.

Recent Insider Activity

Executive transactions at Roivant Sciences have drawn attention from market watchers over the summer. On June 25, 2026, President and CIO Mayukh Sukhatme exercised options for 500,000 shares at a price of $3.85 before selling 500,000 shares at $34.13 for a total value of $17.07 million. On the same day, Eric Venker also acquired 200,000 shares through option exercises at $3.85 before making subsequent sales. Additional sales took place on June 30, 2026, when Keith Manchester sold 200,000 shares for $7.09 million, and both Qvt Financial LP and Daniel Allen Gold disposed of 12,380 shares each for $436,766.

Wall Street Analyst Coverage

Analyst sentiment leans positive, backed by a strong buy recommendation across 12 tracking firms. Stifel began coverage on September 17, 2026, with a buy rating and a $51.00 price target. Earlier in September, TD Cowen maintained its buy rating while lifting its target to $55.00 from $50.00, and Guggenheim kept a buy rating while moving its target to $46.00 from $42.00. HC Wainwright & Co. and Jefferies also reiterated buy views in early September with targets at $47.00 and $52.00 respectively. Meanwhile, Wolfe Research adjusted its stance on October 12, 2026, by downgrading the stock to Peer Perform.

About Roivant Sciences Ltd.

Headquartered in London, Roivant Sciences discovers, develops, and commercializes medicines and delivery technologies through various subsidiary companies. Its clinical pipeline addresses diverse conditions including autoimmune diseases, pulmonary hypertension, and inflammatory disorders.

What's Ahead for Roivant Sciences Ltd.

Market participants will look toward the November 9 earnings report for updates on trial progress and financial metrics. Insider filings will continue to provide visibility into how executives manage their holdings following earlier option exercises and equity sales.